+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06902350

Phase 1 Study of CS231295 to Assess Safety, Tolerability, and Drug Behavior in Adults with Advanced Solid Tumors

Led by Chipscreen Biosciences, Ltd. · Updated on 2025-05-25

102

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating CS231295 in patients with advanced solid tumors, including glioblastoma and small cell lung carcinoma, to assess its safety, tolerability, and how the body processes the drug. This first-in-human study is designed in two phases dose escalation and cohort expansion, aiming to find recommended doses for further studies. The trial is open-label and focuses on patients whose standard treatments have failed or are not suitable. The study involves oral administration of CS231295. During dose escalation, participants receive either a single dose or multiple daily doses, while in the cohort expansion phase, only multiple daily doses are given. Treatment continues until disease progression, intolerable side effects, withdrawal, or study end. The dose-limiting toxicity period is 6 days after single dose and 28 days after the first multiple dose cycle. Participants undergo screening, treatment, and follow-up periods. Researchers monitor for dose-limiting toxicities, adverse events, and pharmacokinetic properties through up to 11 treatment cycles of 28 days each. They also evaluate tumor responses and long-term outcomes such as progression-free and overall survival. Safety and tolerability are carefully observed throughout the study and after treatment completion.

CONDITIONS

Brief Title

Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors

Research Team

X

Xinhang Wang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here